The development of proteasome inhibitors (PIs) and immunomodulatory drugs has 
significantly improved outcomes for patients with relapsed/refractory multiple 
myeloma (RRMM); however, not all patients benefit from treatment with these 
agents and some patients can become drug refractory over time. Due to the 
largely incurable nature of multiple myeloma, the development of newer agents is 
ongoing and includes new oral PIs (ixazomib), immunotherapies (e.g., CD38- or 
SLAMF7-targeted antibodies), and small molecules. This review provides an 
overview of the advances in targeted therapy for patients with RRMM, including 
recently approved agents, with a focus on monotherapy and combined targeted 
therapies.